COMPANY

Eli Lilly

HQ: Indianapolis, IN source · lilly.com ↗

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

791 open jobs · last seen Oct 21, 2026 · 63 sources

Location: Indianapolis, IN · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Obesity Overweight Type 2 Diabetes Mellitus Amyloid C-Reactive Protein Crohn Disease Breast Neoplasms Neoplasm Metastasis Osteoarthritis Atherosclerotic Cardiovascular Disease Type 1 Diabetes Mellitus Alzheimer Disease Amyloid Plaque Ulcerative Colitis Atherosclerosis Irritable Bowel Syndrome Alopecia Areata Type 2 Diabetes Immune Thrombocytopenia Systemic Lupus Erythematosus Rheumatoid Arthritis Metabolic Dysfunction-Associated Steatotic Liver Disease Elevated Lp(a) Overweight or Obesity Plasma Vitiligo Non-Segmental Vitiligo Chronic Obstructive Pulmonary Disease Cardiovascular Diseases Lipoprotein(a) Thyroid Neoplasms Non-Small-Cell Lung Carcinoma Urinary Incontinence,Stress Cognitive Dysfunction Lewy Body Disease Synucleinopathies Cardiovascular Disease Hypertension Chronic Renal Insufficiency Nausea

791+5 patient-care hiddenOpen jobs 2,090Trials (company is sponsor)24FDA records (2 yrs)

Hiring

Title	Location (from posting)	Employer posted	First seen
Territory Manager - Immunology & Neurology	Mumbai, Mahārāshtra, India	Oct 21, 2026	Oct 12, 2026
Senior Technical Engineer – LabVantage Master Data	Hyderabad, Telangāna, India	Oct 21, 2026	Oct 15, 2026
Technical Recruiter M&Q	Houston, Texas, United States of America	Oct 21, 2026	Oct 18, 2026
Brand Manager – CMH, Türkiye	ISTANBUL, Türkiye	Oct 21, 2026	Oct 21, 2026
Information Technology - Infrastructure /Manager /Seishin Manufacturing	KOBE, Hyogo, Japan	Oct 21, 2026	Oct 21, 2026

See all 791 jobs

Trial and FDA signals

New trial + clinical hiring Started a Phase 3 trial (NCT07817875, actual start Sep 25, 2026) (+19 other new trials); 39 clinical-operations roles open. ClinicalTrials.gov NCT07817875 (Sep 25, 2026)
Evidence (20 events)
- Sep 25, 2026 · ClinicalTrials.gov NCT07817875
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-25,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Yea'
- Aug 26, 2026 · ClinicalTrials.gov NCT07794579
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Ob'
- Aug 14, 2026 · ClinicalTrials.gov NCT07775300
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-14,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder'
- Aug 27, 2026 · ClinicalTrials.gov NCT07783802
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event'
- Aug 12, 2026 · ClinicalTrials.gov NCT07641504
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-12,type:ACTUAL}; studyFirstPostDate=2026-06-11; briefTitle='A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain'
- Aug 7, 2026 · ClinicalTrials.gov NCT07759245
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-07,type:ACTUAL}; studyFirstPostDate=2026-08-12; briefTitle='A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)'
- Sep 22, 2026 · ClinicalTrials.gov NCT07808073
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-22,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy'
- Sep 15, 2026 · ClinicalTrials.gov NCT07808060
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-15,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight'
- Sep 11, 2026 · ClinicalTrials.gov NCT07803744
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-11,type:ACTUAL}; studyFirstPostDate=2026-09-04; briefTitle='A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity'
- Sep 9, 2026 · ClinicalTrials.gov NCT07787169
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-09,type:ACTUAL}; studyFirstPostDate=2026-08-26; briefTitle="A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease"
- Sep 2, 2026 · ClinicalTrials.gov NCT07801300
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-09-03; briefTitle='A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)'
- Sep 2, 2026 · ClinicalTrials.gov NCT07818967
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='A Study of Abemaciclib (LY2835219) in Healthy Participants'
- Aug 28, 2026 · ClinicalTrials.gov NCT07794592
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-28,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants'
- Aug 27, 2026 · ClinicalTrials.gov NCT07767487
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A Study of LY4226695 in Healthy Participants'
- Aug 17, 2026 · ClinicalTrials.gov NCT07765498
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-08-14; briefTitle='A Study of LY4355756 in Healthy Participants'
- Aug 11, 2026 · ClinicalTrials.gov NCT07547540
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-11,type:ACTUAL}; studyFirstPostDate=2026-04-23; briefTitle='A Study of LY3971297 in Participants With Heart Failure'
- Jul 31, 2026 · ClinicalTrials.gov NCT07738614
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-07-31; briefTitle='A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight'
- Jul 20, 2026 · ClinicalTrials.gov NCT07707375
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-07-16; briefTitle='A Study of LY4268989 (MORF 057) in Healthy Participants'
- Jul 20, 2026 · ClinicalTrials.gov NCT07701083
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-07-14; briefTitle='A Study of Eloralintide (LY3841136) in Healthy Participants'
- Aug 5, 2026 · ClinicalTrials.gov NCT07612267
  leadSponsor.name='Eli Lilly and Company'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-08-05,type:ACTUAL}; studyFirstPostDate=2026-05-28; briefTitle='A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indicat'
Drug approval + hiring FDA novel approval for ONSWIK (BLA 761408, Sep 23, 2026; +1 other approval); 324 manufacturing/quality or commercial roles open. FDA BLA 761408 (Sep 23, 2026)
Evidence (2 events)
- Sep 23, 2026 · FDA BLA 761408
  openFDA drugsfda: application_number=BLA761408; sponsor_name='ELI LILLY AND CO'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260923; submission_class_code=TYPE 1; brand_name=['ONSWIK']
- Apr 1, 2026 · FDA NDA 220934
  openFDA drugsfda: application_number=NDA220934; sponsor_name='ELI LILLY AND CO'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260401; submission_class_code=TYPE 1; brand_name=['FOUNDAYO']

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

2026-12 Trial start Phase 2: A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer source ↗
2026-10 Trial start Phase 1: A Study of LY4515100 in Healthy Male Participants source ↗
2026-10 Trial start Phase 1: A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) source ↗
2026-10 Trial start Phase 4: A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India source ↗
Sep 25, 2026 FDA FDA New indication / efficacy supplement: OLUMIANT (baricitinib) — NDA207924/9, Sep 25, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 23, 2026 FDA FDA New drug/biologic (novel): ONSWIK (insulin efsitora alfa-gobe) — BLA761408, Sep 23, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 22, 2026 Trial start Phase 1: A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy source ↗
Sep 18, 2026 FDA FDA New indication / efficacy supplement: VERZENIO (abemaciclib) — NDA208716/22, Sep 18, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 18, 2026 FDA FDA New indication / efficacy supplement: INLURIYO (imlunestrant tosylate) — NDA218881/1, Sep 18, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 15, 2026 Trial start Phase 1: A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight source ↗
Sep 9, 2026 Trial start Phase 1: A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease source ↗
Sep 2, 2026 Trial start Phase 1: A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein) source ↗
2026-09 Trial start Phase 1: A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein) source ↗
Aug 27, 2026 FDA FDA New indication / efficacy supplement: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (tirzepatide) — NDA215866/44, Aug 27, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Aug 27, 2026 FDA FDA New indication / efficacy supplement: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (tirzepatide) — NDA215866/45, Aug 27, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Aug 27, 2026 Trial start Phase 2: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event source ↗
Aug 26, 2026 FDA FDA New indication / efficacy supplement: ZEPBOUND; ZEPBOUND (AUTOINJECTOR); ZEPBOUND KWIKPEN (tirzepatide) — NDA217806/41, Aug 26, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Aug 26, 2026 Trial start Phase 3: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity source ↗
Aug 17, 2026 Trial start Phase 1: A Study of LY4355756 in Healthy Participants source ↗
Aug 7, 2026 Trial start Phase 2: A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) source ↗
Jul 20, 2026 Trial start Phase 1: A Study of LY4268989 (MORF 057) in Healthy Participants source ↗
Jul 15, 2026 Trial start Phase 3: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting source ↗
Jul 14, 2026 FDA FDA New indication / efficacy supplement: RETEVMO (selpercatinib) — NDA213246/17, Jul 14, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Jul 14, 2026 FDA FDA New indication / efficacy supplement: RETEVMO (selpercatinib) — NDA218160/7, Jul 14, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Jul 13, 2026 FDA FDA New indication / efficacy supplement: VERZENIO (abemaciclib) — NDA208716/21, Jul 13, 2026. Applicant at approval: Eli Lilly and Company. source ↗

Showing 25 of 74 dated events.

Upcoming milestones

2026-10 (ESTIMATED) · Phase 1 · A Study of LY4268989 (MORF 057) in Healthy Participants · NCT07707375
2026-12 (ESTIMATED) · Phase 1 · A Study of LY4515100 in Healthy Male Participants · NCT07867327
2026-12 (ESTIMATED) · Phase 2 · A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer · NCT07169851
2027-01 (ESTIMATED) · Phase 1 · A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein) · NCT07867340
2027-01 (ESTIMATED) · Phase 1 · A Study of LY4355756 in Healthy Participants · NCT07765498
2027-03 (ESTIMATED) · Phase 2 · A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes · NCT07215559
2027-03 (ESTIMATED) · Phase 2 · A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia · NCT07269210
2027-04 (ESTIMATED) · Phase 1 · A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · NCT07101328

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) Showing 50 of 2,090

Record	Title	Phase	Status	Start	Primary completion
NCT07215559	A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	Phase 2	Active, not recruiting	Oct 16, 2025	2027-03 (estimated)
NCT07533006	A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)	Phase 2	Recruiting	Apr 14, 2026	2027-06 (estimated)
NCT07801300	A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)	Phase 1	Recruiting	Sep 2, 2026	2027-08 (estimated)
NCT07867327	A Study of LY4515100 in Healthy Male Participants	Phase 1	Not yet recruiting	2026-10	2026-12 (estimated)
NCT06897475	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	Phase 2	Recruiting	Mar 28, 2025	2027-05 (estimated)
NCT06721013	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	Phase 1/Phase 2	Recruiting	Jul 30, 2025	2028-02 (estimated)
NCT07867340	A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)	Phase 1	Not yet recruiting	2026-09	2027-01 (estimated)
NCT07483099	A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease	Phase 2	Recruiting	May 4, 2026	2027-06 (estimated)
NCT07707375	A Study of LY4268989 (MORF 057) in Healthy Participants	Phase 1	Active, not recruiting	Jul 20, 2026	2026-10 (estimated)
NCT07174336	A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	Phase 3	Recruiting	Dec 22, 2025	2029-05 (estimated)
NCT07276958	A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)	Phase 1	Recruiting	Feb 4, 2026	2028-03 (estimated)
NCT07153471	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee	Phase 3	Active, not recruiting	Sep 15, 2025	2028-04 (estimated)
NCT07165028	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	Phase 3	Recruiting	Oct 15, 2025	2030-08 (estimated)
NCT06292013	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Phase 3	Active, not recruiting	Mar 5, 2024	2029-03 (estimated)
NCT07353931	Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight	Phase 3	Recruiting	Feb 9, 2026	2028-03 (estimated)
NCT07222332	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)	Phase 3	Recruiting	Feb 5, 2026	2028-07 (estimated)
NCT07843459	A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)	Phase 1	Not yet recruiting	2026-10	2028-07 (estimated)
NCT07533019	A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo	Phase 2	Recruiting	Apr 14, 2026	2027-05 (estimated)
NCT07759245	A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)	Phase 2	Recruiting	Aug 7, 2026	2028-05 (estimated)
NCT07765498	A Study of LY4355756 in Healthy Participants	Phase 1	Recruiting	Aug 17, 2026	2027-01 (estimated)
NCT07186101	LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:	Phase 2	Recruiting	Nov 10, 2025	2027-05 (estimated)
NCT07287098	A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer	Phase 2	Recruiting	May 13, 2026	2029-01 (estimated)
NCT07808073	A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy	Phase 1	Recruiting	Sep 22, 2026	2027-09 (estimated)
NCT07613294	A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk	Phase 3	Recruiting	Jun 1, 2026	2029-12 (estimated)
NCT07822880	A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India	Phase 4	Not yet recruiting	2026-10	2029-10 (estimated)
NCT07787169	A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease	Phase 1	Recruiting	Sep 9, 2026	2028-07 (estimated)
NCT07202884	A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight	Phase 3	Recruiting	Sep 30, 2025	2028-03 (estimated)
NCT07589595	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	Phase 2	Recruiting	May 20, 2026	2028-08 (estimated)
NCT07783802	A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event	Phase 2	Recruiting	Aug 27, 2026	2027-05 (estimated)
NCT07169851	A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer	Phase 2	Recruiting	Nov 28, 2025	2026-12 (estimated)
NCT07827612	A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer	Phase 2	Not yet recruiting	2026-12	2028-07 (estimated)
NCT07219953	A Study of Brenipatide in Participants With Alcohol Use Disorder	Phase 3	Recruiting	Oct 16, 2025	2028-04 (estimated)
NCT06383390	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Phase 3	Active, not recruiting	Apr 30, 2024	2029-02 (estimated)
NCT07223593	Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease	Phase 3	Recruiting	Oct 31, 2025	2028-06 (estimated)
NCT07545772	A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)	Phase 2	Recruiting	Apr 29, 2026	2027-07 (estimated)
NCT07241390	A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)	Phase 3	Recruiting	Dec 1, 2025	2031-08 (estimated)
NCT07545759	A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)	Phase 2	Recruiting	May 6, 2026	2027-09 (estimated)
NCT07794579	A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity	Phase 3	Recruiting	Aug 26, 2026	2029-08 (estimated)
NCT07613307	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting	Phase 3	Recruiting	Jul 15, 2026	2027-05 (estimated)
NCT07483073	A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease	Phase 2	Recruiting	May 4, 2026	2027-06 (estimated)
NCT07213804	A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer	3	Recruiting	Oct 22, 2025	2028-11 (estimated)
NCT07101328	A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )	Phase 1	Recruiting	May 28, 2026	2027-04 (estimated)
NCT07222137	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults	Phase 3	Recruiting	Jan 12, 2026	2031-07 (estimated)
NCT07219173	A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma	Phase 2	Recruiting	Oct 22, 2025	2028-04 (estimated)
NCT07282600	A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes	Phase 3	Recruiting	Dec 15, 2025	2028-01 (estimated)
NCT07415044	LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis	Phase 2	Recruiting	Mar 26, 2026	2030-06 (estimated)
NCT07808060	A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight	Phase 1	Recruiting	Sep 15, 2026	2027-06 (estimated)
NCT07589608	A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight	Phase 2	Recruiting	May 15, 2026	2027-09 (estimated)
NCT07269210	A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia	Phase 2	Recruiting	Dec 8, 2025	2027-03 (estimated)
NCT07369011	A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight	Phase 3	Recruiting	Feb 10, 2026	2028-03 (estimated)

FDA records (last 2 years)

Sep 25, 2026 FDA New indication / efficacy supplement: OLUMIANT (baricitinib) — NDA207924/9, Sep 25, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 23, 2026 FDA New drug/biologic (novel): ONSWIK (insulin efsitora alfa-gobe) — BLA761408, Sep 23, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 18, 2026 FDA New indication / efficacy supplement: VERZENIO (abemaciclib) — NDA208716/22, Sep 18, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Sep 18, 2026 FDA New indication / efficacy supplement: INLURIYO (imlunestrant tosylate) — NDA218881/1, Sep 18, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Aug 27, 2026 FDA New indication / efficacy supplement: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (tirzepatide) — NDA215866/44, Aug 27, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Aug 27, 2026 FDA New indication / efficacy supplement: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (tirzepatide) — NDA215866/45, Aug 27, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Aug 26, 2026 FDA New indication / efficacy supplement: ZEPBOUND; ZEPBOUND (AUTOINJECTOR); ZEPBOUND KWIKPEN (tirzepatide) — NDA217806/41, Aug 26, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Jul 14, 2026 FDA New indication / efficacy supplement: RETEVMO (selpercatinib) — NDA213246/17, Jul 14, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Jul 14, 2026 FDA New indication / efficacy supplement: RETEVMO (selpercatinib) — NDA218160/7, Jul 14, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Jul 13, 2026 FDA New indication / efficacy supplement: VERZENIO (abemaciclib) — NDA208716/21, Jul 13, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Jun 9, 2026 FDA New indication / efficacy supplement: EBGLYSS (lebrikizumab-lbkz) — BLA761306/6, Jun 9, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Apr 1, 2026 FDA New drug/biologic (novel): FOUNDAYO (orforglipron calcium) — NDA220934, Apr 1, 2026. Applicant at approval: Eli Lilly and Company. source ↗
Dec 19, 2025 FDA New indication / efficacy supplement: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (tirzepatide) — NDA215866/39, Dec 19, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Nov 20, 2025 FDA New indication / efficacy supplement: RETEVMO (selpercatinib) — NDA218160/6, Nov 20, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Nov 20, 2025 FDA New indication / efficacy supplement: RETEVMO (selpercatinib) — NDA213246/15, Nov 20, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Sep 25, 2025 FDA New drug/biologic (novel): INLURIYO (imlunestrant tosylate) — NDA218881, Sep 25, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Jul 1, 2025 FDA New indication / efficacy supplement: KISUNLA (donanemab-azbt) — BLA761248/4, Jul 1, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Apr 7, 2025 FDA New indication / efficacy supplement: CYRAMZA (ramucirumab) — BLA125477/49, Apr 7, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Jan 27, 2025 FDA New indication / efficacy supplement: CYRAMZA (ramucirumab) — BLA125477/48, Jan 27, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Jan 15, 2025 FDA New indication / efficacy supplement: OMVOH (mirikizumab-mrkz) — BLA761279/2, Jan 15, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Jan 15, 2025 FDA New indication / efficacy supplement: OMVOH (mirikizumab-mrkz) — BLA761279/3, Jan 15, 2025. Applicant at approval: Eli Lilly and Company. source ↗
Dec 20, 2024 FDA New indication / efficacy supplement: ZEPBOUND; ZEPBOUND (AUTOINJECTOR); ZEPBOUND KWIKPEN (tirzepatide) — NDA217806/13, Dec 20, 2024. Applicant at approval: Eli Lilly and Company. source ↗
Nov 13, 2024 FDA New indication / efficacy supplement: VERZENIO (abemaciclib) — NDA208716/17, Nov 13, 2024. Applicant at approval: Eli Lilly and Company. source ↗
Oct 18, 2024 FDA New indication / efficacy supplement: ZEPBOUND; ZEPBOUND (AUTOINJECTOR); ZEPBOUND KWIKPEN (tirzepatide) — NDA217806/6, Oct 18, 2024. Applicant at approval: Eli Lilly and Company. source ↗

Open jobs 791

5 patient-care jobs hidden (phlebotomy, plasma-center, nursing and similar care roles; 796 open jobs in total).

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Territory Manager - Immunology & Neurology	Mumbai, Mahārāshtra, India	Oct 21, 2026	Oct 12, 2026	Not stated
Senior Technical Engineer – LabVantage Master Data	Hyderabad, Telangāna, India	Oct 21, 2026	Oct 15, 2026	Not stated
Technical Recruiter M&Q	Houston, Texas, United States of America	Oct 21, 2026	Oct 18, 2026	Not stated
Brand Manager – CMH, Türkiye	ISTANBUL, Türkiye	Oct 21, 2026	Oct 21, 2026	Not stated
Information Technology - Infrastructure /Manager /Seishin Manufacturing	KOBE, Hyogo, Japan	Oct 21, 2026	Oct 21, 2026	Not stated
Director - Clinical Research Scientist - Neurodegenerative Disease Early Phase Clinical Development	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Senior Maintenance Technician - Medicine Foundry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Software Product Engineering Technical Lead/Manager - Silicon Valley Hub	South San Francisco, California, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Retail Channel Manager	BOGOTA, Colombia	Oct 20, 2026	Oct 12, 2026	Not stated
Lead Emergency Response Specialist – HSE, Lilly Medicine Foundry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Advisor/Senior Advisor-Prefilled Syringe Platform Lead	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Senior Director, Global Parenteral Drug Product Technical Services (MSAT)	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
HVAC Technician - Lilly Medicine Foundry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Sr. Director of Strategic Partnerships, TuneLab Platform	San Francisco, California, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
Principal - QA API External Manufacturing Peptides	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 12, 2026	Not stated
API Production Operator - Lilly Medicine Foundry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 15, 2026	Not stated
Software Engineer- Full Stack	South San Francisco, California, United States of America	Oct 20, 2026	Oct 15, 2026	Not stated
Utilities Senior Operator - Lilly Medicine Foundry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 15, 2026	Not stated
Senior Analyst - Financial	Ontario, Canada	Oct 20, 2026	Oct 18, 2026	Not stated
Sr. Manager - Quality Control Laboratories	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 18, 2026	Not stated
Advisor - Isotopic Chemistry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 18, 2026	Not stated
Operator-Bulk Warehouse	CAROLINA, Puerto Rico	Oct 20, 2026	Oct 21, 2026	Not stated
Estágio em Transformação Digital \| Tech@Lilly Brasil	Sao Paulo / SP, São Paulo, Brazil	Oct 20, 2026	Oct 21, 2026	Not stated
Scientist, Discovery Oncology (in vivo Biology)	South San Francisco, California, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Associate/Sr. Associate/Manager - Creative Accounts	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Senior Director - Security Posture & Exposure Management	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Advisor/Sr Advisor - Program Governance and Operations - GFD	Allentown, Pennsylvania, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Pharmaceutical Sales Associate Territory Manager - Cardiometabolic Health	Sugar Land, Texas, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Clinical Data Associate	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Director, Translational Pharmacokinetics - DMPK	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Expert Pharmacy Technician, Training Standards	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Advisor- Project Engineer- Design Lead	Pleasant Prairie, Wisconsin, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Senior Director, Drug Safety Operations (remote)	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Sr. Clinical Trial Project Manager	Shanghai, China	Oct 20, 2026	Oct 21, 2026	Not stated
医药代表-心血管健康代谢事业部	Shanghai, China	Oct 20, 2026	Oct 21, 2026	Not stated
Associate Director - Software Engineering	Bangalore, Karnātaka, India	Oct 20, 2026	Oct 21, 2026	Not stated
Sales Representative-CMH-North Taiwan (GP/AH)	TAIPEI, Taipei City, Taiwan	Oct 20, 2026	Oct 21, 2026	Not stated
Sr. Advisor, GQA	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Director, Medical - Clinical Research Scientist	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Project Manager - Tier 2 Major Capital	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Spare Parts Coordinator - Medicine Foundry	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Director - Molecular Dynamics	South San Francisco, California, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Sr. Director - GMP Operations Project Management	Watertown, Massachusetts, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Associate Director, Quality and Standards Pharmacist	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Associate Director, Integration of Automation Pharmacist	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Advisor/Sr Advisor - Program Governance and Operations - GFD	Richmond, Virginia, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
MSL Manager, Türkiye	ISTANBUL, Türkiye	Oct 20, 2026	Oct 21, 2026	Not stated
Associate Director - Development and Manufacturing Procurement	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
ML Ops Engineer	South San Francisco, California, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated
Automation Architect	Indianapolis, Indiana, United States of America	Oct 20, 2026	Oct 21, 2026	Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 791 jobs →